Because MAPK4 expression is associated with patient survival, these result suggest that MAPK4 may serve as a potential synergetic therapeutic target with PARP1 inhibitors in radiotherapy of cervical cancer. This evidence concerns the gene MAPK4 and cervical carcinoma.